Analysis of the protein levels in the cerebrospinal fluid (CSF) of people with late-onset spinal muscular atrophy (SMA) may help to identify biomarkers that not only monitor but also predict Spinraza responses, a study suggests. The results of the study, “Cerebrospinal fluid proteomic profiling…
News
Spine surgery using magnetically controlled growing rods (MCGR) may be an option to correct spinal deformity, or scoliosis, in young children with spinal muscular atrophy (SMA) and avoid the need for repeated surgeries…
Roche has kicked off a worldwide early access program for its experimental therapy risdiplam by making it available to Europeans with the most serious forms of spinal muscular atrophy (SMA). Europeans with SMA type 1 will be able to get it immediately, Roche told SMA News…
Gene therapy administered while newborns are still in the womb may lessen spinal muscular atrophy (SMA) symptoms and prolong survival, a mouse study shows. The study, “Fetal Gene Therapy Using a Single Injection of Recombinant AAV9 Rescued SMA Phenotype in Mice,” was published in the journal Molecular…
For the new year, Cure SMA is stepping up its efforts to get states not testing for spinal muscular atrophy (SMA) at birth to implement the practice — noting that such newborn screenings could dramatically improve patients’ quality of life. Some 17 states began newborn screenings for SMA…
Just 27 days after Nicole Almeida gave birth to her son, Matteo, the baby received a one-time infusion of what one day would be known as Zolgensma. That made him the youngest person ever to receive the world’s most expensive medication. Since that day in August 2015,…
Increasing the amount of ZPR1 — a protein found in low levels in people with spinal muscular atrophy (SMA) — improved motor function and extended the lifespan of a mouse model of SMA, a study reports. The data, which also identified the protein as a direct regulator of the…
An October 2019 protest by adults with spinal muscular atrophy led to an agreement under which all of Romania’s 152 known SMA patients — and those yet to be diagnosed — will gain access to Spinraza (nusinersen), Biogen’s approved treatment for this neuromuscular disease. Romanian doctors began treating…
SMA News Today brought you daily coverage of key findings, treatment developments — including in-depth coverage of Zolgensma’s approval in the U.S. — and of clinical trials related to spinal muscular atrophy (SMA) throughout 2019. We look forward to reporting more of this relevant news to patients, family members, and…
Novartis plans to give up to 100 doses annually of Zolgensma, its costly gene therapy for spinal muscular atrophy (SMA), free-of-charge to eligible young children outside the U.S. with this progressive, neuromuscular disease. These treatments come under a global managed access program (MAP) the company runs for people with…
